FDA approves Pfizer vaccine – UC Santa Cruz scientists explain how it works
soe.ucsc.edu
soe.ucsc.edu
[0] https://www.reuters.com/article/us-health-coronavirus-pfizer...
> ...may miss out on antibodies for other viral proteins...
Do you mean to say that a more traditional one which uses the deactivated virus can help find proteins related to the virus but not specifically targeted, or do you mean that a traditional one could target other proteins that could apply to _other_ viruses?
I'd be getting very outside my lane to speculate on whether inducing immunity against multiple proteins would potentially apply to other viruses also carrying those same proteins - I don't know how specific or how contextual the immune system's response is in this case.
The leading conventional vaccine, the one from AstrZeneca, will be under $4 per dose in the US for the 300 million doses they have agreed to supply to the government, and they have said that they will "in perpetuity" supply it at cost to low and middle income countries.
That will probably make it or another conventional vaccine be the one that makes the biggest difference globally for this pandemic.
Also, the Oxford/Astra Zeneca vaccine isn’t a conventional vaccine but a viral vector vaccine which also has never been approved for use in humans. It acts similarly to the mRNA vaccines but uses a hollowed out adenovirus sheath as the transport mechanism of the RNA into the cell.
https://www.youtube.com/watch?v=the81FQoAUI
Here's a longer 43 minute video explaining them and the Moderna/Pfizer/BioNTech/Astrazeneca clinical trial processes in more detail. The biochem part starts at 12:30.
> Bell’s palsy was reported by four vaccine participants and none in the placebo group. These cases occurred at 3, 9, 37, and 48 days after vaccination. One case (onset at 3 days postvaccination) was reported as resolved with sequelae within three days after onset, and the other three were reported as continuing or resolving as of the November 14, 2020 data cut-off with ongoing durations of 10, 15, and 21 days, respectively. The observed frequency of reported Bell’s palsy in the vaccine group is consistent with the expected background rate in the general population, and there is no clear basis upon which to conclude a causal relationship at this time, but FDA will recommend surveillance for cases of Bell’s palsy with deployment of the vaccine into larger populations.